Establishment and characterization of two breast cancer xenografts in immunodeficient mice for studies on hormone-dependent and hormone-independent tumor growth, progression and invasion
Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.
Autorzy:
Elvebakken H; Department of Oncology, Ålesund Hospital, Møre og Romsdal Hospital Trust, Ålesund, Norway.; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. HjortlandGO; Department of Oncology, Oslo University Hospital, Oslo, Norway. Garresori H; Department of Haematology and Oncology, Stavanger University Hospital, Stavanger, Norway. Andresen PA; Department of Pathology, Oslo University Hospital, Oslo, Norway. Janssen EAM; Department of Pathology, Stavanger University Hospital, Stavanger, Norway.; Department of Chemistry, Bioscience and Environmental Engineering, Stavanger University, Stavanger, Norway. Vintermyr OK; Department of Pathology, Haukeland University Hospital, Bergen, Norway. Lothe IMB; Department of Pathology, Oslo University Hospital, Oslo, Norway. Sorbye H; Department of Oncology, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway.
Pokaż więcej
Źródło:
Journal of neuroendocrinology [J Neuroendocrinol] 2023 Apr; Vol. 35 (4), pp. e13256. Date of Electronic Publication: 2023 Apr 05.
Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway.
Autorzy:
Helland Å; Institute for Cancer Research/Department of Oncology/Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. .; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. . Russnes HG; Institute for Cancer Research/Department of Oncology/Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Pathology, Oslo University Hospital, Oslo, Norway. Fagereng GL; Institute for Cancer Research/Department of Oncology/Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. Al-Shibli K; Dept. of Pathology, Nordland Hospital, Bodø, Norway. Andersson Y; Hospital Pharmacies Enterprise, Oslo, Norway. Berg T; Department of Pathology, University Hospital in North of Norway, Tromsø, Norway.; Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway. Bjørge L; Haukeland University Hospital, Bergen, Norway.; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway. Blix E; Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway.; Department of Oncology, University Hospital in North of Norway, Tromsø, Norway. Bjerkehagen B; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Pathology, Oslo University Hospital, Oslo, Norway. Brabrand S; Institute for Cancer Research/Department of Oncology/Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. Cameron MG; Hospital of Southern Norway, Kristiansand, Norway. Dalhaug A; Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway.; Department of Oncology and Palliative Medicine, Nordland Hospital Trust, Bodø, Norway. Dietzel D; Telemark Hospital Trust, Skien, Norway. Dønnem T; Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway.; Department of Oncology, University Hospital in North of Norway, Tromsø, Norway. Enerly E; Department of Research, The Cancer Registry of Norway, Oslo, Norway. Flobak Å; Department of Oncology, The Cancer Clinic, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.; Department of Clinical and Molecular Medicine, The Norwegian University of Science and Technology (NTNU), Trondheim, Norway. Fluge S; Helse Fonna, Haugesund, Norway. Gilje B; Stavanger University Hospital, Stavanger, Norway. Gjertsen BT; Haukeland University Hospital, Bergen, Norway.; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway. Grønberg BH; Department of Oncology, The Cancer Clinic, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.; Department of Clinical and Molecular Medicine, The Norwegian University of Science and Technology (NTNU), Trondheim, Norway. Grønås K; Patient Representative, Oslo University Hospital, Oslo, Norway. Guren T; Institute for Cancer Research/Department of Oncology/Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. Hamre H; Akershus University Hospital, Lørenskog, Norway. Haug Å; Haukeland University Hospital, Bergen, Norway. Heinrich D; Innlandet Hospital Trust, Lillehammer, Norway. HjortlandGO; Institute for Cancer Research/Department of Oncology/Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. Hovig E; Institute for Cancer Research/Department of Oncology/Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.; Centre of Bioinformatics, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway. Hovland R; Head of Section for Cancergenomics Section for Cancer Genomics, Haukeland University Hospital, Bergen, Norway. Iversen AC; Patient Representative, Oslo University Hospital, Oslo, Norway. Janssen E; Section for Cancergenomics, Department of Pathology, Stavanger University Hospital, Stavanger, Norway.; Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway. Kyte JA; Institute for Cancer Research/Department of Oncology/Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. von der Lippe Gythfeldt H; Innlandet Hospital Trust, Lillehammer, Norway. Lothe R; Institute for Cancer Research/Department of Oncology/Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Lund JÅ; Dept of Oncology, Helse Møre and Romsdal Health Trust, Ålesund, Norway.; Dept of Health Sciences, NTNU, Ålesund, Norway. Meza-Zepeda L; Institute for Cancer Research/Department of Oncology/Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. Munthe-Kaas MC; Department of Pediatric Medicine, Oslo University Hospital, Oslo, Norway. Nguyen OTD; Northern Trøndelag Trust, Levanger, Norway. Niehusmann P; Department of Pathology, Oslo University Hospital, Oslo, Norway. Nilsen H; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Pathology, Oslo University Hospital, Oslo, Norway. Puco K; Institute for Cancer Research/Department of Oncology/Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.; Department of Oncology, Haematology and Palliative Care, Lovisenberg Diaconal Hospital, Oslo, Norway. Ree AH; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Akershus University Hospital, Lørenskog, Norway. Riste TB; Dept of Pathology, Førde Hospital Trust, Førde, Norway. Semb K; Department of Oncology, Vestfold Hospital Trust, Tønsberg, Norway. Steinskog ESS; Haukeland University Hospital, Bergen, Norway. Stensvold A; Department of Oncology, Kalnes Hospital, Grålum, Norway. Suhrke P; Department of Pathology, Vestfold Hospital Trust, Tønsberg, Norway. Tennøe Ø; Department of Oncology, Kalnes Hospital, Grålum, Norway. Tjønnfjord GE; Department of Haematology, Oslo University Hospital, Tønsberg, Norway. Vassbotn LJ; Dept of Oncology, Førde Hospital Trust, Førde, Norway. Aas E; Institute of Health and Society, Department of Health Management and Health Economics, University of Oslo, Oslo, Norway.; Division for Health Services, Norwegian Institute of Public Health, Oslo, Norway. Aasebø K; Haukeland University Hospital, Bergen, Norway. Tasken K; Institute for Cancer Research/Department of Oncology/Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Smeland S; Institute for Cancer Research/Department of Oncology/Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Volumetric parameters from [ F]FDG PET/CT predicts survival in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms.
Autorzy:
Langen Stokmo H; Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. Aly M; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Department of Radiology, Asyut University Hospital, Asyut, Egypt. Bowitz Lothe IM; Department of Pathology, Oslo University Hospital, Oslo, Norway. Borja AJ; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Mehdizadeh Seraj S; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Ghorpade R; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Miao X; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. HjortlandGO; Department of Oncology, Oslo University Hospital, Oslo, Norway. Malinen E; Department of Medical Physics, Oslo University Hospital, Oslo, Norway.; Department of Physics, University of Oslo, Oslo, Norway. Sorbye H; Department of Oncology, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway. Werner TJ; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Alavi A; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Revheim ME; Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Pokaż więcej
Źródło:
Journal of neuroendocrinology [J Neuroendocrinol] 2022 Jul; Vol. 34 (7), pp. e13170. Date of Electronic Publication: 2022 Jun 21.
Typ publikacji:
Journal Article; Observational Study; Research Support, Non-U.S. Gov't
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway.
Autorzy:
Helland Å; Institute for Cancer Research/Department of Oncology /Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. .; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. . Russnes HG; Institute for Cancer Research/Department of Oncology /Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Pathology, Oslo University Hospital, Oslo, Norway. Fagereng GL; Institute for Cancer Research/Department of Oncology /Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. Al-Shibli K; Dept. of Pathology, Nordland Hospital, Bodø, Norway. Andersson Y; Hospital Pharmacies Enterprise, Oslo, Norway. Berg T; Department of Pathology, University Hospital in North of Norway, Tromsø, Norway.; Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway. Bjørge L; Haukeland University Hospital, Bergen, Norway.; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway. Blix E; Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway.; Department of Oncology, University Hospital in North of Norway, Tromsø, Norway. Bjerkehagen B; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Pathology, Oslo University Hospital, Oslo, Norway. Brabrand S; Institute for Cancer Research/Department of Oncology /Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. Cameron MG; Hospital of Southern Norway, Kristiansand, Norway. Dalhaug A; Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway.; Department of Oncology and Palliative Medicine, Nordland Hospital Trust, Bodø, Norway. Dietzel D; Telemark Hospital Trust, Skien, Norway. Dønnem T; Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway.; Department of Oncology, University Hospital in North of Norway, Tromsø, Norway. Enerly E; Department of Research, The Cancer Registry of Norway, Oslo, Norway. Flobak Å; Department of Oncology, The Cancer Clinic, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.; Department of Clinical and Molecular Medicine, The Norwegian University of Science and Technology (NTNU), Trondheim, Norway. Fluge S; Helse Fonna, Haugesund, Norway. Gilje B; Stavanger University Hospital, Stavanger, Norway. Gjertsen BT; Haukeland University Hospital, Bergen, Norway.; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway. Grønberg BH; Department of Oncology, The Cancer Clinic, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.; Department of Clinical and Molecular Medicine, The Norwegian University of Science and Technology (NTNU), Trondheim, Norway. Grønås K; Patient Representative, Oslo University Hospital, Oslo, Norway. Guren T; Institute for Cancer Research/Department of Oncology /Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. Hamre H; Akershus University Hospital, Lørenskog, Norway. Haug Å; Haukeland University Hospital, Bergen, Norway. Heinrich D; Innlandet Hospital Trust, Lillehammer, Norway. HjortlandGO; Institute for Cancer Research/Department of Oncology /Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. Hovig E; Institute for Cancer Research/Department of Oncology /Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.; Centre of Bioinformatics, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway. Hovland R; Head of Section for Cancergenomics Section for Cancer Genomics, Haukeland University Hospital, Bergen, Norway. Iversen AC; Patient Representative, Oslo University Hospital, Oslo, Norway. Janssen E; Section for Cancergenomics, Department of Pathology, Stavanger University Hospital, Stavanger, Norway.; Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway. Kyte JA; Institute for Cancer Research/Department of Oncology /Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. von der Lippe Gythfeldt H; Innlandet Hospital Trust, Lillehammer, Norway. Lothe R; Institute for Cancer Research/Department of Oncology /Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Lund JÅ; Dept of Oncology, Helse Møre and Romsdal Health Trust, Ålesund, Norway.; Dept of Health Sciences, NTNU, Ålesund, Norway. Meza-Zepeda L; Institute for Cancer Research/Department of Oncology /Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. Munthe-Kaas MC; Department of Pediatric Medicine, Oslo University Hospital, Oslo, Norway. Nguyen OTD; Northern Trøndelag Trust, Levanger, Norway. Niehusmann P; Department of Pathology, Oslo University Hospital, Oslo, Norway. Nilsen H; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Pathology, Oslo University Hospital, Oslo, Norway. Puco K; Institute for Cancer Research/Department of Oncology /Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.; Department of Oncology, Haematology and Palliative Care, Lovisenberg Diaconal Hospital, Oslo, Norway. Ree AH; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Akershus University Hospital, Lørenskog, Norway. Riste TB; Dept of Pathology, Førde Hospital Trust, Førde, Norway. Semb K; Department of Oncology, Vestfold Hospital Trust, Tønsberg, Norway. Steinskog ESS; Haukeland University Hospital, Bergen, Norway. Stensvold A; Department of Oncology, Kalnes Hospital, Grålum, Norway. Suhrke P; Department of Pathology, Vestfold Hospital Trust, Tønsberg, Norway. Tennøe Ø; Department of Oncology, Kalnes Hospital, Grålum, Norway. Tjønnfjord GE; Department of Haematology, Oslo University Hospital, Tønsberg, Norway. Vassbotn LJ; Dept of Oncology, Førde Hospital Trust, Førde, Norway. Aas E; Institute of Health and Society, Department of Health Management and Health Economics, University of Oslo, Oslo, Norway.; Division for Health Services, Norwegian Institute of Public Health, Oslo, Norway. Aasebø K; Haukeland University Hospital, Bergen, Norway. Tasken K; Institute for Cancer Research/Department of Oncology /Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Smeland S; Institute for Cancer Research/Department of Oncology /Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms.
Autorzy:
Pommergaard HC; ENETS Neuroendocrine Tumor Centre of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Surgery and Transplantation, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Nielsen K; ENETS Neuroendocrine Tumor Centre of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Surgery and Transplantation, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Endocrinology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Sorbye H; Department of Oncology, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway. Federspiel B; ENETS Neuroendocrine Tumor Centre of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Pathology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Tabaksblat EM; ENETS Neuroendocrine Tumor Centre of Excellence, Aarhus University Hospital, Aarhus, Denmark.; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. Vestermark LW; Department of Oncology, Odense University Hospital, Odense, Denmark. Janson ET; ENETS Neuroendocrine Tumor Centre of Excellence, Uppsala University Hospital, Uppsala, Sweden.; Department of Medical Sciences, Endocrine Oncology, Uppsala University, Uppsala, Sweden. Hansen CP; ENETS Neuroendocrine Tumor Centre of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Surgery and Transplantation, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Ladekarl M; ENETS Neuroendocrine Tumor Centre of Excellence, Aarhus University Hospital, Aarhus, Denmark.; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark. Garresori H; Department of Oncology, Stavanger University Hospital, Stavanger, Norway. HjortlandGO; ENETS Neuroendocrine Tumor Centre of Excellence, Oslo University Hospital, Oslo, Norway.; Department of Oncology, Oslo University Hospital, Oslo, Norway. Sundlöv A; Department of Oncology, Skåne University Hospital, Lund, Sweden. Galleberg R; Department of Oncology, Haukeland University Hospital, Bergen, Norway. Knigge P; ENETS Neuroendocrine Tumor Centre of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Endocrinology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, University of Copenhagen and Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Kjaer A; ENETS Neuroendocrine Tumor Centre of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, University of Copenhagen and Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Langer SW; ENETS Neuroendocrine Tumor Centre of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Knigge U; ENETS Neuroendocrine Tumor Centre of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Surgery and Transplantation, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Endocrinology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Pokaż więcej
Źródło:
Journal of neuroendocrinology [J Neuroendocrinol] 2021 May; Vol. 33 (5), pp. e12967. Date of Electronic Publication: 2021 Mar 26.
PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3.
Autorzy:
Ali AS; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden. Langer SW; Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. Federspiel B; Department of Pathology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. HjortlandGO; Department of Oncology, Oslo University, Oslo, Norway. Grønbæk H; Department of Hepatology & Gastroenterology, Aarhus University Hospital, Aarhus, Denmark. Ladekarl M; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark. Welin S; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden. Weber Vestermark L; Department of Oncology, Odense University Hospital, Odense, Denmark. Arola J; Pathology, HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Osterlund P; Department of Oncology, Helsinki University Hospital and Helsinki University, Helsinki Finland.; Department of Oncology, Tampere University Hospital and Tampere University, Tampere, Finland. Knigge U; Department of Surgery C and Endocrinology PE, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Sørbye H; Department of Oncology, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Bergen, Norway. Micke P; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. Grimelius L; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. Grönberg M; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden. Tiensuu Janson E; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2020 Dec 14; Vol. 15 (12), pp. e0243900. Date of Electronic Publication: 2020 Dec 14 (Print Publication: 2020).
Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.
Autorzy:
Ali AS; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden. Grönberg M; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden. Federspiel B; Department of Pathology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. Scoazec JY; Department of Biopathology, Institut Gustave Roussy, Villejuif, France. HjortlandGO; Department of Oncology, Oslo University, Oslo, Norway. Grønbæk H; Department of Hepatology & Gastroenterology, Aarhus university Hospital, Aarhus, Denmark. Ladekarl M; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. Langer SW; Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. Welin S; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden. Vestermark LW; Department of Oncology, Odense University Hospital, Odense, Denmark. Arola J; Pathology, HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Österlund P; Department of Oncology, Helsinki University Hospital and Helsinki University, Helsinki Finland.; Department of Oncology, Tampere University Hospital, Tampere, Finland. Knigge U; Department of Surgery C and Endocrinology PE, Rigshospitalet, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark. Sorbye H; Department of Oncology, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Bergen, Norway. Grimelius L; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. Janson ET; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2017 Nov 07; Vol. 12 (11), pp. e0187667. Date of Electronic Publication: 2017 Nov 07 (Print Publication: 2017).
Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft.
Autorzy:
Skrbo N; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. HjortlandGO; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Department of Oncology, Oslo University Hospital, Oslo, Norway. Kristian A; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; K.G. Jebsen Centre for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway. Holm R; Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. Nord S; Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; K.G. Jebsen Centre for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway. Prasmickaite L; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. Engebraaten O; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Department of Oncology, Oslo University Hospital, Oslo, Norway; Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; K.G. Jebsen Centre for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway. Mælandsmo GM; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Cancer Stem Cell Innovation Centre, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway; Department of Pharmacy, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway; K.G. Jebsen Centre for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway. Sørlie T; Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Cancer Stem Cell Innovation Centre, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway; K.G. Jebsen Centre for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway. Andersen K; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Cancer Stem Cell Innovation Centre, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2014 Nov 24; Vol. 9 (11), pp. e113278. Date of Electronic Publication: 2014 Nov 24 (Print Publication: 2014).
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
